Receptor conversion impacts outcomes of different molecular subtypes of primary breast cancer.

ABSTRACT:

Background

Although the conversion of clinically used breast cancer biomarkers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) between primary tumors and metastatic lesions is well recognized, data on whether receptor conversion has an effect on therapy management and survival in patients with metastatic breast cancer is limited. This study aimed to investigate the clinical implications of receptor conversion throughout tumor progression.

Methods

In total, 2450 patients diagnosed with metastatic breast cancer in Tianjin Medical University Cancer Institute and Hospital were analyzed and 426 female patients with available biopsy results from both primary and metastatic sites were included in this study. We investi

SUBMITTER: Zhao W 

PROVIDER: S-EPMC8111518 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature